Skip to main content
. 2022 Jul 13;11(3):1375–1390. doi: 10.1007/s40120-022-00384-2

Fig. 4.

Fig. 4

TSQM outcomes at 24 months versus BL in subgroup analysis of patients previously treated with first-line injectable DMTs. Wilcoxon signed-rank test; *p < 0.05; **p < 0.0001 versus baseline